Active, not recruitingPhase 2NCT05321420
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PureTech
- Principal Investigator
- Camilla Graham, MDPureTech
- Intervention
- Placebo(drug)
- Enrollment
- 240 enrolled
- Eligibility
- 40 years · All sexes
- Timeline
- 2022 – 2025
Study locations (30)
- University of Alabama Birmingham, Birmingham, Alabama, United States
- Science 37, Los Angeles, California, United States
- NewportNativeMD, Inc., Newport Beach, California, United States
- Paradigm Clinical Research Centers, Inc., Redding, California, United States
- Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California, United States
- University of Connecticut Health Center, Farmington, Connecticut, United States
- Accel Research Sites Network, DeLand, Florida, United States
- Harmony Medical Research Institute, Inc, Hialeah, Florida, United States
- Piedmont Healthcare, Inc., Atlanta, Georgia, United States
- Clinical Research Investments, Decatur, Georgia, United States
- Indiana University School of Medicine, Indianapolis, Indiana, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Pulmonix, Greensboro, North Carolina, United States
- Southeastern Research Center, Winston-Salem, North Carolina, United States
- University of Cincinnati, Cincinnati, Ohio, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05321420 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGNANCT07466420Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.Katerina M. Antoniou
- RECRUITINGPHASE3NCT07299695Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary FibrosisArgyrios Tzouvelekis
- RECRUITINGPHASE2NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisContineum Therapeutics